1. Volume 64, Issue 2, Pages 301-307 (February 2016)
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks 
Jordan J. Feld, Christophe Moreno, Roger Trinh, Edward Tam, Stefan Bourgeois, Yves Horsmans, Magdy Elkhashab, David E. Bernstein, Ziad Younes, Robert W. Reindollar, Lois Larsen, Bo Fu, Kevin Howieson, Akshanth R. Polepally, Andreas Pangerl, Nancy S. Shulman, Fred Poordad 
Journal of Hepatology 
Volume 64, Issue 2, Pages (February 2016)
DOI: /j.jhep
Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

2. Journal of Hepatology 2016 64, 301-307DOI: (10. 1016/j. jhep. 2015. 10
Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

3. Fig. 1
Virologic response during and after treatment with OBV/PTV/r+DSV for 12weeks. The percentage of patients achieving HCV RNA <25IU/ml response at different time points is plotted with 95% CI using the Wilson score method. The horizontal dashed line indicates the non-inferiority margin for the historical rate achieved with sofosbuvir plus PegIFN/RBV (72.7%), and the horizontal solid line indicates the superiority threshold (83.2%). RVR, rapid virologic response at treatment week 4; EOTR, end of treatment response at week 12; SVR4, sustained virologic response at post-treatment week 4; SVR12, sustained virologic response at post-treatment week 12.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2015 European Association for the Study of the Liver Terms and Conditions